Literature DB >> 1359021

An immunogenetic heterogeneity in multiple sclerosis.

J Hillert1, M Grönning, H Nyland, H Link, O Olerup.   

Abstract

Two clinical forms of multiple sclerosis (MS), primarily chronic progressive MS (PCP MS) and relapsing/remitting MS (R/R MS) have been shown to differ in several respects. The results of genomic HLA class II typing with restriction fragment length polymorphism analysis of 62 MS patients from Western Norway, 42 with R/R MS and 20 PCP MS, are reported on here. As in previous studies of Swedish patients, the haplotype DRw17(3), DQw2 was found to be five times more common in R/R MS than in PCP MS. This finding supports the hypothesis that R/R and PCP MS are immunogenetically separate entities. In contrast with a previous investigation of Norwegian MS patients, no association of MS with glutamine at position 34 of the HLA-DQ alpha chain or with defined sequences of the HLA-DQB1 gene was found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359021      PMCID: PMC1015182          DOI: 10.1136/jnnp.55.10.887

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  Pathogenesis of progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D G MacManus; D P Kingsley; B E Kendall; I F Moseley; W I McDonald
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  Clinical factors associated with increased disability in multiple sclerosis.

Authors:  U Leibowitz; M Alter
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

3.  Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?

Authors:  R Van Lambalgen; E A Sanders; J D'Amaro
Journal:  J Neurol Sci       Date:  1986-11       Impact factor: 3.181

4.  HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus.

Authors:  J A Todd; J I Bell; H O McDevitt
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

5.  HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology.

Authors:  B Carlsson; J Wallin; J Böhme; E Möller
Journal:  Hum Immunol       Date:  1987-10       Impact factor: 2.850

6.  HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

Authors:  M Madigand; J J Oger; R Fauchet; O Sabouraud; B Genetet
Journal:  J Neurol Sci       Date:  1982-03       Impact factor: 3.181

7.  Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic amino acid sequences.

Authors:  F Vartdal; L M Sollid; B Vandvik; G Markussen; E Thorsby
Journal:  Hum Immunol       Date:  1989-06       Impact factor: 2.850

8.  HLA-DR and DQ DNA genotyping in multiple sclerosis patients in Northern Ireland.

Authors:  C G Cullen; D Middleton; D A Savage; S Hawkins
Journal:  Hum Immunol       Date:  1991-01       Impact factor: 2.850

9.  Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing.

Authors:  J S Lanchbury; M A Hall; K I Welsh; G S Panayi
Journal:  Hum Immunol       Date:  1990-02       Impact factor: 2.850

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  14 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Genetic analysis of multiple sclerosis.

Authors:  Alastair Compston; Stephen Sawcer
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis.

Authors:  J M Greer; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

5.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

6.  The prevalence of multiple sclerosis in the Leeds Health Authority.

Authors:  H L Ford; E Gerry; C M Airey; A Vail; M H Johnson; D R Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

7.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

8.  Surveying multiple sclerosis in the United Kingdom.

Authors:  N Robertson; A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

9.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease.

Authors:  G Giovannoni; J W Thorpe; D Kidd; B E Kendall; I F Moseley; A J Thompson; G Keir; D H Miller; M Feldmann; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.